5 / 10
Volume 7, Issue 6 (Suppl)
Clin Exp Pharmacol, an open access journal
ISSN: 2161-1459
Page 15
Notes:
December 14-16, 2017 Rome, Italy
International Conference on
2
nd
International Conference on
&
Toxicology and Clinical Pharmacology
Generic Drugs and Biosimilars
CO-ORGANIZED EVENT
Improving compliance with EMA and FDA pediatric regulations by improving the efficiency of
pediatric drug development
W
hile the list of unmet needs in child-appropriate drugs remains long, so does the list of R&D challenges, including
recruitment of patients, availability of experienced investigators, high development costs, and increasingly complex
regulatory requirements. Prioritization of where to place resources is needed to help pediatric drug devel¬opers comply with
regulations and set up frameworks for efficient pediatric drug R&D. In this presentation, we will discuss the hierarchy of
clinical trial data and how to ascertain the efficiency of each step and arrive at estimates for the numbers of assessments,
exposures, participants, etc. Pediatric drug development typically necessitates accessing dozens of sites in multiple countries
just for a single study, which entails managing inevitable logistical issues, both planned and unplanned, while having to
complete trials in a short time frame with long term follow-up. Responding to these challenges can be accomplished through
a stakeholders’ working group of drug developers, patient advocacy organizations, academic partners, and regulatory agencies
that can establish priorities and deliv-erables, while enhancing close cooperation and responsive communication. Also critical
is the recognition that because of complications ranging from age-based variability in dosage forms to formulation stability,
oral dosage forms can be challenging but globally placed pediatric-specific formulation developers are addressing the strong
interest in developing alternatives to injectables.
Biography
Christopher Milne joined the Center for the Study of Drug Development at the Tufts University School of Medicine (Tufts CSDD) in 1998 as a Senior Research Fellow and
has published over 70 book chapters, white papers, and journal articles. Currently, his research interests include: academic-industry collaborations; disease, demographic
and market access factors in the emerging markets; incentive programs for pediatric studies, orphan products, neglected diseases, breakthrough therapies, and medical
countermeasures (MCMs); and, tracking the progress of new regulatory and research initiatives such as regulatory science, translational medicine, personalized medicine,
and FDA User Fee programs.
Christopher.Milne@tufts.eduChristopher Milne, Clin Exp Pharmacol 2017, 7:6(Suppl)
DOI: 10.4172/2161-1459-C1-024
Christopher Milne
Tufts University, USA